ClinicalTrials.Veeva

Menu
M

Metro Boston Clinical Partners | Brighton, MA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ruxolitinib
Povorcitinib
Guselkumab
Difamilast
ABP 501
ABP 654
Lebrikizumab
MT-7117
Humira®
MK-6194
0

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 20 total trials

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-61...

Active, not recruiting
Non-segmental Vitiligo
Biological: MK-6194
Drug: Placebo

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Placebo
Drug: Povorcitinib

This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Drug: Placebo

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Enrolling
Prurigo Nodularis
Drug: Placebo
Drug: Povorcitinib

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-...

Active, not recruiting
Scalp Psoriasis
Plaque Psoriasis
Drug: Placebo
Drug: Guselkumab

The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate...

Active, not recruiting
Moderate Plaque Psoriasis
Drug: Placebo
Drug: Guselkumab

The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of one or two intramuscular injections of the Acne mRNA vaccine candi...

Enrolling
Acne
Biological: Acne mRNA vaccine
Other: Placebo

Trial sponsors

Incyte logo
Janssen (J&J Innovative Medicine) logo
Acrotech Biopharma logo
Amgen logo
Lilly logo
Kadmon logo
Merck Sharp & Dohme (MSD) logo
Mitsubishi Tanabe Pharma logo
Sanofi logo
Sanofi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems